Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873869 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04873869: Clinical Trial Phase 2 study, sponsored by Neurocrine Biosciences.
NCT04873869 is a Phase 2 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04873869, a Phase 2 study, was terminated before completion, sponsored by Neurocrine Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
Interventions
- DRUG Placebo
- DRUG NBI-921352
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2023-03-17 |
| Phase | Phase 2 |
Why NCT04873869 stopped before completion
NCT04873869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04873869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04873869 about?
NCT04873869 is a clinical study titled "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)". The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
What is the current status of trial NCT04873869?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-01-31. Estimated completion is 2023-03-17.
What interventions are being tested in trial NCT04873869?
The interventions under investigation include: Placebo (DRUG), NBI-921352 (DRUG).
Who is sponsoring clinical trial NCT04873869?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04873869's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI